Proinflammatory cytokines and sickness behavior in rheumatic diseases

Current Pharmaceutical Design

Volumn 14, Issue 13, 2008, Pages 1242-1260

  Lorton, Dianne ^a,b   Lubahn, C L ^a,b   Zautra, A J ^b   Bellinger, D L ^c  

^a SUN HEALTH RESEARCH INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cytokines; Immune system; Nervous system; Rheumatoid arthritis; Sickness behavior; Signaling

Indexed keywords

ADRENALIN; ALPHA ADRENERGIC RECEPTOR; AURINTRICARBOXYLIC ACID; BETA ADRENERGIC RECEPTOR; CAPSAICIN; CITALOPRAM; CLOMIPRAMINE; CYTOKINE; FLUOXETINE; GAMMA INTERFERON; GLUCOCORTICOID; GLUTATHIONE; IMIPRAMINE; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; LITHIUM; MOCLOBEMIDE; NORADRENALIN; PAROXETINE; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VENLAFAXINE;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; AMNESIA; ANOREXIA; ATTENTION DISTURBANCE; BINDING SITE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; CHOROID PLEXUS; COGNITIVE DEFECT; CONCENTRATION LOSS; CYTOKINE PRODUCTION; DELIRIUM; DEPRESSION; DISEASE ACTIVITY; DRUG MEGADOSE; EVENING DOSAGE; FATIGUE; FEVER; GLIA CELL; HOMEOSTASIS; HUMAN; HYPERALGESIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; IMMUNOREGULATION; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MENTAL DISEASE; NONHUMAN; PAIN; PERIPHERAL NERVE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RHEUMATOID ARTHRITIS; SENSORY NERVE; SEXUAL DEVIATION; SIGNAL TRANSDUCTION; STRESS; VAGOTOMY; VAGUS NERVE; VIRUS INFECTION; WEIGHT REDUCTION;

EID: 47349115734     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208799316375     Document Type: Review

References (276)

1. Besedovsky H, del Rey A. Immune-neuro-endocrine interactions: Facts and hypotheses. Endocr Rev 1996; 17: 64-102.
2. Maier S, Watkins L. Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev 1998; 105: 83-107.
3. Blalock JE. The immune system as the sixth sense. J Intern Med 2005; 257: 126-38.
4. Hart BL. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 1988; 12: 123-37.
5. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson W, et al. Cytokine-induced sickness behavior. Brain Behav Immun 2003; 17(Suppl 1): S112-8.
6. Rooney M, David J, Symons J, Di Giovine F, Varsani H, Woo P. Inflammatory cytokine responses in juvenile chronic arthritis. Br J Rheumatol 1995; 34: 454-60.
7. Prieur AM, Roux-Lombard P, Dayer JM. Dynamics of fever and the cytokine network in systemic juvenile arthritis. Rev Rheum Engl Ed 1996; 63: 163-70.
8. Elliott MJ, Woo P, Charles P, Long-Fox A, Woody JN, Maini RN. Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). 1997. Br J Rheumatol 1997; 36: 589-93.
9. Weinberger A, Kesler A, Pinkhas J. Fever in various rheumatic diseases. Clin Rheumatol 1985; 4: 258-66.
10. Zeisberger E, Roth J. Tolerance to pyrogens. Ann N Y Acad Sci 1998; 856: 116-31.
11. Roth J, Hopkins SJ, Hoadley ME, Tripp A, Aslan T, Storr B, et al. Fever and production of cytokines in response to repeated injections of muramyl dipeptide in guinea-pigs. Pflugers Arch 1997; 434: 525-33.
12. American Psychiatric Association. Fourth Text Revision (DSM-IV-TR). Washington DC, American Psychiatric Association 2000.
13. Creed F, Ash G. Depression in rheumatoid arthritis. Int Rev Psychiatry 1992; 4: 23-34.
14. Wells KB, Stewart A, Hays RD, Burnam MA, Rogers W, Daniels M, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989; 262 909-14
15. Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993; 20: 790-6
16. Zautra A. Hamilton N, Potter P, Smith B. Field research an the relationship between stress and disease activity in rheumatoid arthritis. Ann NY Acad Sci 1999; 876: 397-412.
17. Fishbain DA, Cutler R, Rosomoff HL, Rosomoff RS. Chronic pain-associated depression: Antecedent or consequence of chronic pain? A review. Clin J Pain 1997; 13: 116-37.
18. von Knorring L, Perris C, Eisemann M, Eriksson U, Perris H. Pain as a symptom in depressive disorders. II. Relationship to personality traits as assessed by means of KSP. Pain 1983; 17: 377-84.
19. Wörz R. Pain in depression-depression in pain. Pain: Clin Updates 2003; 11: 14.
20. Zautra AJ, Yocum DC, Villanueva I, Smith B, Davis MC, Attrep J, et al. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol 2004; 31: 457-63.
21. Zautra AJ, Smith BW. Depression and reactivity to stress in older women with rheumatoid arthritis and osteoarthritis. Psychosom Med 2001; 63: 687-96.
22. Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, et al. The relationship of depression and stressors to immunological assays: A meta-analytic review. Brain Behav Immun 2001; 15: 199-226
23. Sluzewska A, Rybakowski J, Bosmans E, Sobieska M, Berghmans R, Maes M, et al. Indicators of immune activation in major depression. Psychiatry Res 1996; 64: 161-67.
24. Maes M, Smith R, Scharpe S. The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology 1995; 20: 111-6.
25. Maes M. The immunoregulatory effects of antidepressants. Hum Psychopharmacol 200l; 16: 95-103.
26. Cavallo MG, Pozzilli P. Thorpe R. Cytokines and autoimmunity. Clin Exp Immunol 1994; 96: 1-7.
27. Hutchinson GA, Nehall JE, Simeon DT. Psychiatric disorders in Systemic Lupus Erythematosus. West Indian Med J 1996; 45: 48-50.
28. Pincus T, Griffith J, Pearce S, Isenberg D. Prevalence of self-reported depression in patients with rheumatoid arthritis. Br J Rheumatol 1996; 35: 879-83.
29. Kahl KG, Kruse N, Faller H, Weiss H, Rieckmann P. Expression of tumor necrosis factor-alpha and interferon-gamma mRNA in blood cells correlates with depression scores during an acute attack in patients with multiple sclerosis. Psychoneuroendocrinology 2002; 27: 671-81.
30. Pollak Y, Orion E, Goshen I, Ovadia H, Yirmiya R. Experimental autoimmune encephalomyelitis-associated behavioral syndrome as a model of 'depression due to multiple sclerosis. Brain Bchav Immun 2002; 16; 533-43.
31. Hirano D, Nagashima M, Ogawa R, Yoshino S. Serum levels of interleukin 6 and stress related substances indicate mental stress condition in patients with rheumatoid arthritis. J Rheumatol 2001; 28: 490-95.
32. Spath-Schwalbe E, Hansen K, Schmidt F, Schresenmeier H, Mfarshall L, Burger K, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab 1998; 83: 1573-9.
33. Trask PC, Paterson AG, Siper P, Pau J, Redman Longitudinal course of depression, fatigue, and quality of life inpatients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004; 13: 526-36.
34. Scheibel RS, Valentine AD, O'Brien S, Meyers CA. Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 2004; 16: 185-91.
35. Capuron L. Ravaud A, Miller AH, Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 2004; 18: 205-13.
36. Dantzer R, Wollman E, Vitkovic L, Yirmiya R. Cytokines and depression: fortuitous or causative association? Mol Psychiatry 1999; 4: 328-32
37. Makino M, Kitano Y, Hirohashi M, Takasuna K. Enhancement of immobility in mouse forced swimming test by treatment with human interferon. Eur J Pharmacol 1998; 356: 1-7.
38. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res 1996; 711: 163-74.
39. Swiergiel AH, Smagin GN, Dunn AJ. Influenza virus infection of mice induces anorexia: Comparison with endotoxin and interleukin-1 and the effects of indomethacin, Pharmacol Biochem Behav 1997; 57: 389-96.
40. Swiergiel AH, Smagin GN, johnson LJ, Dunn A. The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: Effects f acute and chronic administration of the interleukin-1 receptor antagonist(IL-1ra). Brain Res 1997; 776: 96-104.
41. Anisman H, Kokkinidis L, Borowski T, Merali Z. Differential effects of interleukin (EL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res 1998; 779: 177-87.
42. Avitsur R, Pollak Y, Yirmiya R. Different receptor mechanism mediate the effects of endotoxin and interleukin-1 on female sexual behavior. Brain Res 1997; 773: 149-61.
43. Avitsur R, Cohen E, Yirmiya R. Effects of interleukin-1 on sexual attractivity in a model of sickness behavior. Physiol 'Behav 1997; 632: 5-30.
44. Capuron L, Dantzer R. Cytokines and depression: The need for a new paradigm. Brain Behav Immun 1003; 17: S119-24.
45. Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001; 24: 531-44.
46. Castanon N, Bluthe RM, Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1beta in the rat. Psychopharmacology (Berl) 2001; 154: 50-60.
47. Castanon N, Leonard BE, Neveu PJ, Yirmiya R. Effects of antide-pressants on cytokine production and actions. Brain Behav Immun 2002; 16: 569-74.
48. Castanon N, Medina C, Mormede C, Dantzer R. Chronic administration of tioneptine balances lipopolysaccharide-induced expression of cytokines in the spleen and hypothalamus of rats. Psycho-neuroendocrinology 2004; 29: 778-90.
49. Castanon N, Konsman JP, Medina C, Chauvet N, Dantzer R. Chronic treatment with the antidepressant tianeptine attenuates lipopolysaccharide-induced Fos expression in the rat paraventricular neucleus and HPA axis activation. Psychoneuroendocrinology 2003; 28: 19-34.
50. Xia Z, De Pierre JW, Nassberger L. Tricyclic antidepressants inhibit EL-6, IL-1beta and TNF-alpha release in human blood monocytes and IL-2 and interferon-gamma in T cells. Immunopharmacology 1996; 34: 27-37.
51. Xia A, Depierre JW, Nassberger L. Modulation of apoptosis induced by tricyclic antidepressants in human peripheral lymphocytes. J Bio Chem Mol Toxicol 1998; 12: 115-23.
52. Bluthé R, Walter V, Parnet F, Laye S, Lestage J, Verrier D, et al. Comptes Rendus de l'Académie des Sciences. Série III, Sciences de la Vie 1994; 499-503.
53. Bluthé RM, Michaud B, Delhaye-Bouchand N, Mariani J, Dantzer R. Hypersensitivity of lurcher mutant mice to the depressing effects of lipopolysaccharide and interleukin-1 on behavior. Neuroreport 1997; 8: 1119-22.
54. Bluthé RM, Jafarian-Tehrani M, Michaud B, Haour F, Dantzer R, Homo-Delarche F. Increased sensitivity of prediabetic nonobese diabetic mouse to the behavioral effects of EL-1. Brain Behav Immun 1999; 13: 303-14.
55. Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum 1998; 41: 2230-7.
56. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol 1996; 23: 1406-17.
57. Swain MG. Fatigue in chronic disease. Clin Sci 2000; 99: 1-8.
58. Kent S, Bluthe RK Kelley KW, Dantzer R. Sickness behavior as a new target for drug development. Trends Pharmacol Sci 1992; 13: 24-8.
59. Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ, et al. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA 1992; 89: 9117-20.
60. Spadaro F, Dunn AJ. Intracerebroventricular administration of interleukin-1 to mice alters investigation of stimuli in a novel environment. Brain Behav Immun 1990; 4: 308-22.
61. Vgontzas AN, Papanicolqou DA, Bixler EO, Kales A, Tyson D, Chrousos GP. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: Role of sleep distrubance and obesity. J Clin Endocrinol Metab 1997; 82: 1313-6.
62. Papanicuolaou D, Wilder RL, Manolagas SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998; 128: 127-37.
63. Gordon MS, Nemunaitis J, Hofman R, Paquette RI, Rosenfeld C, Manfreda S, et al. A phase I trial of recombinant human interleukia-6 in patients with melodysplastic syndromes and thrombocytopenia. Blood 1995; 85: 3066-76.
64. Plevris JN, Blair C, Cossar Dollinger MM, O'Carroll RE, Hayes PC. Chronic fatigue is associated with increased interleukin-6 levels in patients with chronic liver disease. Hepatology 1997; 26:A1818.
65. Wolfe F. Fatigue assessments in rheumatoid arthritis: Comparative performance of visual analog scales and longer fatigue questionnaires in 7760 patients. J Rheumatol 2004; 31: 1896-1902.
66. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbam CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 2003; 48: 35-45.
67. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26: 112S-21S.
68. Abramov YB, Kozlocv AY, Sinel'shchikova OS, Torgovanova GV. Nociceptive reactions during stimulation of immunity in rats with different individual sensitivities to stress. Neurosci Behav 2003; 33: 821-6.
69. Maier SF, Wiertelak EP, Martin D, Watkins LR. Interleukin-1 mediates behavioral hyperalgesia produced by lithium chloride and endotoxin. Brain Res 1993; 623: 321-24.
70. Watkins LR, Maier SF. Implications of immune-to-brain communication for sickness and pain. Proc Natl Acad Sci USA 1999; 96: 7710-3.
71. Watkins LR, Maier SF, Goehler LE. Cytokine-to-brain communication: A review & analysis of alternative mechanisms. Life Sci 1995; 57:1011-26.
72. Wieseler-Frank J, Maier SF, Watkins LR. Immune-to brain communication dynamically modulates pain: Physiological and pathological consequences. Brain Behav Immun 2005; 19: 104-11.
73. Watkins LR, Maier SR. Glia: A novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003; 2: 973-85.
74. Garrison CJ, Dougherty PM, Kajander KC, Carlton SM. Staining of glial fibrillary acidic protein (GFAP) in lumber spinal cord increases following sciatic ncive constriction irjury. Brain Res 1991; 265: 1-7
75. Garrison CJ, Dougherty PM, Carlton SM. GFAP expression in lumbar spinal cord of naive and neuropathic rats treated with MK-801. Exp Neurol 1994; 129: 237-43.
76. Sweitzer SM, Colburn RW, Rutkowski M, Deleo JA. Acute peripheral inflammation induces moderate glial activation and spinal EL-1beta expression that correlates with pain behavior in the rat. Brain Res 1999; 829: 209-21.
77. Fu K, Light AR, Matsushima GK, Maixner W. Microglial reactions after subcutaneous formalin injection into the rat hind paw. Brain Res 1999; 825: 59-7.
78. Watkins LR, Maier SF. The pain of being sick: Implications of immune-to-brain communication for understanding pain. Annu Rev Psychol 2000; 51: 29-57.
79. DeLeo JA, Colburn RW. Proinflammatory cytokines and glial cells: Their role in neuropathic pain. In: Watkins L Ed, Cytokines and pain. Birkhauser 1999; 159-82.
80. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, et al. Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 1999; 19: 10886-97.
81. Colburn RW, Rickman AJ, DeLeo JA. The effect of site and type of nerve injury on spinal glial activtion and neuropathic pain behavior. Exp Neurol 1999: 157: 289-304.
82. Popovich PG, Guan Z, Wei P, Stokes BT. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997; 443-64.
83. Milligan ED, O'Connor KA, Nguyen KT, Armstrong CB, Twining C, Gaykema RP, et al. Intrathecal HIV-1 envelope glycoprotein gp120 induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci 2001; 21: 2808-19.
84. Marriott DR, Wilkin GP. Substance p receptors on O-2A progenitor cells and type-2 astrocytes in vitro. J Neurochem 1993; 16: 826-34.
85. Takuma K, Matsuda T, Hashimoto H, Kitanaka J, Asano S, Kishida Y, et al. Role of Na(+)-Ca2+ exchanger in agonist-induced Ca2+ signaling in cultured rat astrocytes. J Neurochem 1996; 67: 1840-45.
86. Maciajewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB. Characterization of fractalkine in rat brain cells: Migratory and activation signals for CX3CR-1-expressing microglia. J Immunol 1999; 163: 1628-35.
87. Chapman GA, Moores K, Harrison D, Campblel CA, Stewart BR, Strijbos PJ. Fractalkine cleavage from neuronal membranes represent an acute event in the inflammatory response to excitotoxic brain damage. J Neurosci 2000; 20: RC87 1-5.
88. Inoue A, Ikoma K, Morrioka N, Kumagai K, Hashimoto T, Hide I, et al. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. J Neurochem 1999; 73: 2206-13.
89. Southall MD, Michael RL, Vasko M. Intrathecal NSAIDS attenuate inflammation-induced neuropeptide release from rat spinal cord slices. Pain 1998; 78: 39-48.
90. Meller ST, Dykstra C, Grzybycki D, Murphy S, Gebhart GF. The possible role of glia in nociceptive processing and hyperalgesia in the spinal card of the rat. Neuropharmacology 994; 33: 1471-8.
91. Watkins LR, Martin D, Ulrich P, Tracey KJ, Maier SF. Evidence for the involvement of spinal cord glia in subcutaneous formalin induced hyperalgesia in the rat. Pain 1997; 71: 225-35.
92. Sweitzer SM, Schubert P, DeLeo JA. Propentofylline, a glial modulating agent, exhibits anti-allodynic properties in a rat model of neuropathic pain. J Pharmacol Exp Ther 2001; 297: 1210-7.
93. Hashizume H, DeLeo JA, Colburn RW, Weinstein JN. Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine 2000; 25: 1206-17.
94. Milligan ED, Mehmert KY, Hinde JL, Harvey LO, Martin D, Tracey KY, et al. Thermal hyperalgesia and mechanical allodynia produced by intrathecal administration of the human immunodeficiency-1 envelope hlycoprotein, gp120. Brain Res 2000; 861: 105-16.
95. Watkins LR, Maier SF. Immune regulation of central nervous system functions: From sickness responses to pathological pain. J Intern Med 2005; 257: 139-55.
96. Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL. Cytokine involvement in dynorphin-induced allodynia. Pain 2000; 84: 159-67.
97. Tadano T, Namioka M, Nakagawasai O, Tan-No K, Matsushima K, Endo Y, et al. Induction of nociceptive responses by intrathecal injection of inteleukin-1 in mice. Life Sci 1999; 65: 255-61.
98. DeLeo JA, Colburn RW, Nichols M, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996; 695-700.
99. Straub RH, Harle P. Sympathetic neurotransmitters in joint inflammation. Rheum Dis Clin North Am 2005; 31: 43-59.
100. Miller L, Justen H, Cutolo M, Scholmerich J, Straub R. The loss of sympathetic nerve fibers in the synovial tissue of patients with rheumatoid arthritis is accompanied by increased norepinephrine release from synovial macrophages. FASEB J 2000; 14: 2097-107.
101. Mapp P, Walsh D, Garrett N, Kidd B, Curwys S, Polak J, et al. Effect of three animal models of inflammation on nerve fibres in the synovium. Ann Rheum Dis 1994; 53: 240-6.
102. Lorton D, Lubhan C, Bellinger DL. Potential use of drugs that target neural-immune pathways in the treatment of rheumatoid arthritis and other autoimmune diseases. Cur Drug Targets Inflam Allergy 2003; 2: 1-30.
103. Lorton D, Lubahn C. Catecholamines, sympathetic innervation and immunity: Role in experimental and rheumatoid arthritis. Lett Drug Des Discov 2004; 1: 148-62.
104. Kuis W, De Jong-De Vos Van Steenwijk C, Sinnema G, Davelaars A, Prakken B, Helders P, et al. The autonomic nervous system and the immune system in juvenile rheumatoid arthritis. Brain Behav Immun 1996; 10: 387-98.
105. Leden I, Eriksson A, Lilja B, Sturfelt G, Sundkvist G. Autonomic nerve function in rheumatoid arthritis of varying severity. Scand J Rheumatol 1983; 12: 166-70.
106. Perry F, Heller P, Kamiya J, Levine J. Altered autonomic function in patients with arthritis or with chronic myofascial pain. Pain 1989; 39: 77-84.
107. Kalliomaki J, Saariman H, Toivanen P. Axon reflex sweating in rheumatoid arthritis. Ann Rheum Dis 1963; 22: 46-9.
108. Gozke E, Erdogan N, Akyuz G, Turan B, akyuz E, Us O. Sympathetic skin response and R-R interval variation in cases with rheumatoid arthritis. Electromyogr Clin Neurophysiol 2003; 43: 81-4.
109. Malysheva OA, Trufakin SV, Shirinskii VS. Nerve regulation of cardiac rhythm in rheumatoid arthritis and multiple sclerosis patients. Ter Arkh 2002; 74: 48.
110. Geenen R, Godaert GL, Jacobs JW, Peters ML, Bijlsma JW. Diminished autonomic nervous system responsiveness in rheumatoid arthritis of recent onset. J Rheumatol 1996; 23: 258-64.
111. Levine J, Fye K, Holler P, Basbaum A, Whiting-O'Keefe Q. Clinical response to regional intravenous guanethidine in patients with rheumatoid arthritis. J Rheumatol 1986; 13: 1040-43.
112. Szolcsanyi J. Capsaicin-sensitivc sensory nerve terminal with local and systemic efferent functions: Facts and scopes of an unorthodox neuroregulatory mechanism. Prog Brain Res 1996; 113: 343-59.
113. Lin Q, Zou X, Fang L, Willis WD. Sympathetic modulation of acute cutaneous flare induced by intradermal injection of capsaicin in anesthetized rats. J Neurophysiol 2003; 89: 853-61.
114. Konttinen YT, Kemppinen P, Segerberg M, Hukkanen M, Rees R, Santavirta S, et al. Peripheral and spinal neural mechanisms in arthritis, with particular reference to treatment of inlfmamtion and pain. Arthritis Rheum 1994; 37: 965-82.
115. Schaible HG, Grubb BD. Afferent and spinal mechanisms of joint pain. Pain 1993; 55: 5-54.
116. Drummond PD. Enhancement of thermal hyperalgesia by alpha-adrenoceptors in capsaicin-treated skin. J Auton Nerv Syst 1998; 69: 96-102.
117. Janig W, Levine J, Michaelis M. Interactions of sympathetic and primary afferent neurons following nerve injury and tissue trauma. Prog Brain Res 1996; 113: 161-84.
118. Spengler R, Allen R, Remick, D, Strieter R, Kunkel S. Stimulation of alpha-adrenergic receptor augments the production of macrophage-derived tumor necrosis factor. J Immunol 1990; 145: 1430-4.
119. Chou RC, Dong X, Noble B, Knight P. Spengler R. Adrenergic regulation of macrophage-derived tumor necrosis factor-a generation during a chronic polyarthritis pain model. 1998. J Neuroimmunol 1998; 82: 140-48.
120. Chou R, Dong X, Noble B, Knight PSR. β-adrenergic receptor regulation of macrophage-derived tumor necrosis factor-a production from rats with experimental arthritis. J Neuroinmumol 1996; 67: 7-16.
121. Spengler R, Chensue S, Giacherio D, Blenk N, Kunkel S. Endogenous norepinephrine regulates tumor necrosis factor-α production from macrophages in vitro. J Immunol 1994; 152: 3024-31.
122. Heijnen C, van der Voort C, Wulffraat N, van der Net J, Kuis W, Kavelaars A. Functional α1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis. J Neuroimmunol 1996; 71: 223-6.
123. Kavelaars A. Regulated expression of alpha-1 adrenergic receptors in the immune system. Brain Behav Immun 2002; 16: 799-807.
124. Bao L, Zhu Y, Elhassan AM, Wu Q, Xiao B, Zhu J, et al. Adjuvant-induced arthritis: IL-1beta, IL-6 and TNF-alpha are upregulated in the spinal cord. Neuroreport 2001; 12: 3905-8.
125. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996; 39: 2035-45.
126. Dick B, Eccleston C, CrombeZ G. Attentional functioning in fibromyalgia, rheumatoid arthritis, and musculoskeletal pain patients. Arthritis Rheum 2002; 47: 639-44.
127. Appenzeller S, Bertolo MB, Costallat LT. Cognitive impairment in rheumatoid arthritis. Methods Find Exp Clin Pharmacol 2004; 26: 339-43.
128. Tiersky LA, Johnson SK, Lange G, Natelson BH, DeLuca J. Neuropsychology of chronic fatigue syndrome: A critical review. J Clin Exp Neuropsychol 1997; 19: 560-86.
129. Glanz BI, Slonim D, Urowitz MB, Gladman DD, Gough J, MacKinnon A. Pattern of neurospychologic dysfunction in inactive systemic laps erythematosus. Neuropsych Neuropsychol Behav Neurol 1997; 10: 232-8.
130. Aubert A, Vega C, Dantzer R, Goddall G. Pyrogens specifically disrupt the acquistion of a task involving cognitive processes in the rat. Brain Behav human 1995; 9: 129-48.
131. Gibertini M, IL-1beta impairs relational but not procedural rodent learning in a water-maze task. Adv Exp Med Biol 1996; 402: 207-17.
132. Gibertini M, Newton C, Friedman H, Klein TW. Spatial learning impairment in mice infected with Legionella pneumophila or administered exogenous interleukin-1 beta. Brain Behav Immun 1995; 9: 113-28.
133. Oitzl MS, van Oers H, Schöbltz B, De Kloet ER. Interleukin-1ß but not interleukin-ß, impairs spatial navigation learning. Brain Res 1993; 613: 160-3.
134. Lynch AM, Walsh C, Delaney A, Nolan Y, Campbell vA, Lynvh A. Lipopolysaccharide-induced increase in signalling in hippocampus is abrogated by EL-10-a role for IL-1 beta? J Neurochem 2004; 88: 635-46
135. Vereker E, O'Donnell E, Lynch A, Kelly A, Nolan Y, Lynch MA. Evidence that interleukin-1 beta and reactive oxygen species production play a pivotal role in stress-induced impairment of LTP in the rat dentate gyrus. Eur J Neurosci 2001; 14: 1809-19.
136. Kelly A, Lynch A, Vereker E, Nolan Y, Queenan P, Whittaker E, et al. The anti-inflammatory cytokine, interleukin (IL)-10, blocks the inhibitory effect of IL-1 beta on long term potentiation. A role for JNK. J Biol Chem 2001; 276: 45564-72.
137. Murray CA, Lynch MA. Evidence that increased hippocampal expression of the cytokine interleukin-1 beta is a common trigger for age- and stress-induced impairments in long-term potentiation. J Neurosci 1998; 18: 2974-81.
138. Kelly A, Vereker E, Nolan, Brady M, Barry C, Loscher CE, et al. Activation of p38 plays a pivotal role in the inhbitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. J Biol Chem 2003; 278: 19453-62.
139. Pugh CR, Kumagawa K, Fleshner M, Watkins LR, Maier SF, Rudy JW. Selective effects of peripheral lipopolysaccharide edministration on contextual and auditory-cuc fear conditioning. Brain Behav Immun 1998; 12: 212-29.
140. Barrientos RM, Higgins EA, Sprunger DB, Watkins LR, Rudy JW, Maier SF. Memory for context is impaired by a post context exposure injectin of interleukin-1 beta dorsal hippocampus. Behav Brain Res 2002; 134: 291-8.
141. Hanisch UK, Quirion R. Interleukin-2 as a neuroregulatory cytokine. Brain Res Brain Res Rev 1995; 21: 246-84
142. Anisman H, Merali Z. Anhedonic and anxiogenic effects of cytokine exposure. Adv Exp Med Biol 1999; 461: 199-233
143. Yirmiya R. Depression in medical illness: The role of the immune system. West J Med 2000; 173: 333-6.
144. Meyers CA. Mood and cognitive disorders in cancer patients receiving cytokine therapy. Adv Exp Med Biol 1999; 461: 75-81
145. Walker LG, Walker MB, Heys SD, Lolley J, Wesnes Y, Eremin O. The psychological and psychiatric effects of rIL-2 therapy: A controlled clinical trial. Psychooncology 1997; 6: 290-301.
146. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
147. Maeier S, Watkins L, Nance D. Multiple routes of action of interleukin-1 on the nervous system. In: Ader R, Felten DL, Cohen N Eds, Pschoneuroimmunology, San Diego, Academic Press. 2001; 563-84.
148. Dantzer R, Bluthé R-M, Castanon N, Chauvet N, Capuron L, Goodal G, et al. Cytokine effects on behavior. In: Ader R, Felten DL, Cohen N Eds, Pschoneuroimmunology, San Diego. Academic Press 2001; 703-27.
149. Callahan MK, Ransohoff RM. Analysis of leukocyte extravasation across the blood-brain barrier: Conceptual and technical aspects. Curr Allergy Asthma Rep 2004; 4: 65-74.
150. Mayhan WG. Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Res 2002; 927: 144-52.
151. Didier N, Romero IA, Creminon C, Wijkhuisen A, Grassi J, Mabondzo A. Secretion of interleukin-1 beta by astrocytes mediates endothelin-1 and tumour necrosis flactor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem 2003; 86: 246-54.
152. Kim KS, Wass A, Cross AS, Opal SM. Modulation of blood-brain barier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine Cytokine Res 1992; 11: 293-98.
153. Ferrari CC, Depino AM, Prada F, Muraro N, Campbell S, Podhajcer O, et al. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am J Pathol 2004; 165: 1827-37.
154. Blatteis CM. Neuromodulation actions of cytokines. Yale J Biol Med 1990; 63: 133-42.
155. Saper CB, Breder C. The neurological bais of fever. New Eng J Med 1994; 330: 1880-6.
156. Ericsson A, Arias C, Sawchenko P. Evidence for an intramedullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J Neurosci 1997; 17: 7166-79.
157. Lee HY, Whiteside MB, Herkenham M. Area postrema removal abolishes stimulatory effects of intravenous IL-1 on HPA activity and c-fos in RNA in the hypothalamic paraventricular nucleus. Brain Res Bull 1998; 46: 495-503.
158. Kakucska I, Qi Y, Clark B, Lechan RM. Endotoxin-induced corticotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus is mediated centrally by interleukin-1. Endocrinology 1993; 133: 815-21.
159. Klir JJ, McClellan JL, Kluger MJ. Interleukin-1β causes the increase in anterior hypothalamic interleukin-6 during LPS-induced fever in rats. Am J Physiol 1994; 266: R1845-8.
160. Banks WA, Kastin AJ. Minireview: Saturable transport of peptides across the blood-brain barrier. Life Sci 1987; 41: 1319-38.
161. Banks WA, Oritz L, Plotkin SR, Kastin AJ. Human IL-1 alpha, murine IL-1 alpha, and marine EL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther 1991; 259: 988-96.
162. Gutierrez EG, Banks W, Kastin A. Murine TNF alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993; 47: 169-76.
163. Banks WA, Kastin AJ, Durham DA. Bidirectional transport of interleukin-1 alpha across the blood-brain barrier. Brain Res Bull 1989; 23: 433-7
164. Ericsson A, Liu C, Hart RP, Sawchenko PE. Type 1 interleukin-1 receptor in the rat brain: Distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J Comp Neurol 1995; 361: 681-98.
165. Wong M-L, Licinio J. Localization of interleukin-1 type 1 receptor mRNA in rat brain. Neuroimmunomodulation 1994; 1: 110-5.
166. Yabuuchi K, Minami M, Katsumata S, Satoh M. Localization of type 1 interleukin-1 receptor mRNA in the rat brain. Mol Brain Res 1994; 27: 27-36.
167. 2 activates fever producting autonomic. J Neurosci 1996; 16: 6246-54.
168. Lacroix S, Rivest S. Effect of acute systemic inflammation response and cytokines on the transcription of the gcncs encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem 1998; 70: 452-66.
169. Cao C, Matsumura K, Yamagata K, Watanabe Y. Endothelial cells of the rat brain vasculature express cyclooxygenase 2 mRNA in response to systemic interleukin-1ß: A possible site of prostaglandin synthesis responsible for fever. Brain Res 1996; 73: 263-72.
170. Breder CD, Saper CB. Expression of inducible cyclooxygenase mRNA in the mous brain after systemic administration of bacterial lipopolysaccharide. Brain Res 1996; 713: 64-9.
171. Elmquist JK, Scammell TE, Saper CB. Mechanism of CNS response to systemic immune challenge: The febrile response. Trends Neurosci 1997; 20: 565-70.
172. Matsumura K, Cao C, Ozaki M, Morii H, Nakadate K, Watanabe Y. Brain endothelial cells express cyclooxygenase-2 during lipopolysaccharide-induced fever: Light and electron microscopic immunocytochemical studies. J NeuroSci 1998; 18: 6279-89.
173. Van Dam A-M, Brouns M, Louisse S, Berken-Bosch F. Immunocytochemical detection of prostaglandin E2 in microvasculature and in neurons of rat brain after administration of bacterial endotoxin. Brain Res 1993; 613: 331-6.
174. Quan N, Stern EL, Whiteside MB, Herkenham M. Induction of pro-inflammatory cytokine mRNAs in the brain after peripheral injection of subseptic doses of lipopolysaccharide in the rat J Neuroimmunol 1999; 93: 72-80.
175. Ericsson A, Kovacs K, Sawchenko P. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine. J Neurosci 1994; 14: 897-913.
176. Wan W, Janz L, Vriend C, Sorensen C, Greenerg A, Nance D. Differential induction of c-fos immunoreactivity in hypothalamus and brain stem nuclei following central and peripheral administration of endotoxin. Brain Res Bull 1993; 32: 581-7.
177. Brady LS, Lynn AB, Herkenham M, Gottesfeld A. Systemic interleukin-1 induces early and late patterns of c-fos mRNA expression in brain. J Neurosci 1994; 14: 4951-64.
178. Wan W, Wetmore L, Sorensen CM, Greenberg AH, Nance DM. Neural and
179. Matsumara K, Watanabe Y, Imai-Matsumura K, Connolly M, Koyama Y, Onoe H, et al. Mapping of prostaglandin E2 binding sites in rat brain using quantitative autoradiography. Brain Res 1992; 581: 292-8.
180. MacNeil BJ, Jansen AH, Janz LJ, Greenberg AH, Nance DM. Peripheral endotoxin increases splenic sympathetic nerve activity via central prostaglandin synthesis. Am J Physiol 1997; 273: R609-14.
181. Katsuura G, Gottschall PE, Kahl RR, Arimura A. Adrenocorticotropin release induced by intracerebroventricular injection of recombinant human interleukin-1 in rats: Possible involvement of prostaglandin. Endocrinology 1988; 122: 1773-9.
182. Kluger MJ. Fever: Role of pyrogens and cryogens. Physiol Rev 1991; 71: 93-127.
183. Blalock JE, Smith ES, Meyer WJ. The pituitary-adrenocortical axis and the immune system. Clin Endocrinol Metabol 1985; 14: 1021-38.
184. 2 during lipopolysaccharide-induced fever in guinea pigs. Brain Res Bull 1996; 39: 391-9.
185. Gaykema RP, Dijkstra I, Tilders FJH. Subdiaphragmatic vagotomy suppresses endotoxin-induced activation of hypothalamic corticotropin-releasing hormone neurons d ACTH secretion. Endocrinol 1995; 136: 4717-20.
186. Niijima A. An electrophysiological study on the autonomic innervatin of the mesenteric lymph node in the rat. Neurosci 1998; 243: 144-6.
187. Bret-Diabat J-L, Bluthé RM, Kent S, Kelley DW, Dantzer R. Lipopolysaccharide and interleukin-1 depress food-motivated behavior in mice by a vagal-mediated mechanism. Brain Behav Immun 1995; 9: 242-6.
188. Watkins L, Goehler L, Relton J, Tartaglia N, Silbert L, Martin D, et al. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: Evidence for vagal mediation of immunebrain communication. Neurosci Lett 1995; 183: 27-31.
189. Laye S, Bluthe R, Kent S, Combe C, Medina C, Parnet P, et al. Subdiaphragmatic vagotomy blocks induction of IL-1b mRNA in mice brain in response to peripheral LPS. Regulatory Integrative Comp Physiol 1995; 37: R1327-31.
190. Bluthé RM, Michaud B, Kelley KW, Dantzer R. Vagotomy attenuates behavioral effects of interleukin-1 injected peripherally but not centrally. Neuroreport 1996; 7: 1485-8
191. Bluthé RM, Michaud B, Kelley KW, Dantzer R. Vagotomy blocks behavioral effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport 1996; 7: 2823-7.
192. Milligan ED, Nguyen KT, Deak T, Hinde JL, Fleshner M, Watkins LR, et al. The long term acute phase-like responses that follow acute stressor exposure are blocked by alpha-melanocyte stimulating hormone. Brain Res 1998; 810: 48-8.
193. Romanovsky AA, Kulchitsky VA, Simons C, Sugimoto N, Szekeley M. Cold defense mechanisms in vagotomized rats. Am J Physiol 1997; 273: R784-9.
194. Ek M, Kuroswaw M, Lundeherg T, Ericsson A. Activation of vagal afferents after intravenous injection of interleukin-1ß: Role of endogenous prostaglandins. J Neurosci 1998; 18: 9471-9.
195. Goehler LE, Gaykema RPA, Nguyen KT, Lee JE, Tilders FJH, Maier SF, et al. Interleukin-1ß in immune cells of the abdominal vagus nerve: An immune to nervous system link? J Neurosci 1999; 19: 2799-806.
196. Luheshi G, Stefferl A, Turnbull A, Dascombe M, Brouwer S, Hopkins S, et al. Febrile response to tissue inflammation involves both peripheral and brain EL-1 and TNF-alpha in the rat. Am J Physiol 1997; 272: R862-8.
197. Turnbull A, Pitossi F, Lebrun J, Lee S, Meltzer J, Nance D, et al. Inhibition of tumor necrosis factor-alpha action within the CNS markedly reduces the plasma adrenocorticotropin response to peripheral local inflammation in rats. J Neurosci 1997; 17: 3262-73.
198. Wang J, Ando T, Dunn AJ. Effect of homologous interteukin-1, interleukin-6 and tumor necrosis factor-alpha on the core body temperature of mice. Neuroimmunomodulation 1997; 4: 230-6.
199. Myers RR, Wagner R, Sorkin LS. Hyperalgesic action of cytokines on peripheral nerves. In: Watkins LR, Maier SF Ed. Basel, Birkhauser Press 1999.
200. Miller AJ, Luheshi GN, Rothwell NJ, Hopkins SJ. Local cytokine induction by LPS in the rat air pouch and its relationship to the febrile response. Am J Physiol 1997; 272: R857-61.
201. Miller AJ, Hopkins SJ, Luheshi GN. Sites of action of EL-1 in the development of fever and cytokine responses to tissue inflammation in the rat. Br J Pharmacol 1997; 120: 1274-9.
202. Roth J, Störr B, Martin D, Voigt K, Zeisberger E. The role of local induction of tumor necrosis factor by LPS within a subcutaneous air pouch in the development of a febrile response in guinea pigs. Neuroimmunomodualtion 2000; 7: 169-76.
203. Ross G, Roth J, Störr B, Voigt K, Zeisberger E. Afferent nerves are involved in the febrile response to injection of LPS into artificial subcutaneous chambers in guinea pigs. Physiol Behav 2000; 71: 305-13
204. Romeo HE, Tio DL, Rahman SU, Chiannelli F, Taylor AN. The glossopharyngeal nerve as a novel pathway in immune-to-brain communication: Relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol 2001; 115: 91-100.
205. Gourine AV, Rudolph K, Korsak AS, Kubatko J, Tesfaigzi J, Kozak W, et al. Role of capsaicin-sensitive afferent in fever and cytokine response during systemic local inflammation in rats. Neuroimmunomodulation 2001; 9: 13-22.
206. Szekely M, Balasko M, Romanovsky AA. Peripheral neural inputs. Their role in fever development. Ann NY Acad Sci 1997; 813: 427-34.
207. Watanabe T, Morimoto A, Tan N, Makisumi T, Shimada SG, Nakamori T, et al. ACTH response induced in capsaicin-densitized rats by intravenous injectin of interleukin-1 or prostaglandin E. J Physiol 1994; 475: 139-45.
208. Gatti S, Bartfai T. Induction of tumor necrosis factor α mRNA in the brain after peripheral endotoxin treatment Comparison with interleukin-1 family and interleukin-6. Brain Res 1993; 624: 291-5.
209. Layé S, Parnet P, Goujon E, DAntzer R. Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice. Brain Res 1994; 27: 157-62.
210. Hopkins SJ, Rothwell NJ. Cytokines and the nervous system. I. Expression and recognition. Trends Neurosci 1995; 18: 83-7.
211. Layé S, Gheusi G, Cremona S, Combe C, Kelley KW, Santzer R, et al. Endogenous interleukin-1 mediate lipopolysaccharide-induced anorexia and brain cytokine expression. Am J Physic Regul Integr Comp PhysioI 2000; 279: R93-8.
212. Buttini M, Boddeke H. Peripheral lipopolysaccharide stimulation induces interleukin-1b messenger RNA in rat brain microglial cells. Neurosci 1995; 65: 523-30.
213. Van Dam A-M, Brouns M, Louisse S, Berken-Bosch F. Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: A pathway for the induction of non-specific symptoms of sickness. Brain Res 1992; 598: 291-6.
214. Breder CD, Hazuka C. Ghayur T, Klug C, Huginin M, Yasuda K, et al. Regional induction of tumor necrosis factor α expression in the mouse brain after systemic lipopolysaccharide administration. Proc Natl Acad Sci USA 1994; 91: 11393-7.
215. Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL)-1b, IL-1 receptor antagonist, IL-10, and EL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathological implications. Proc Natl Acad Sci. USA 1997; 94: 227-32.
216. Parnet P, Amindari S, Wu C, Brunke-Reese D, Goujon E, Weyhenmeyer JA, et al. Expression of type I and type II interleukin-1 receptors in mouse brain. Brain Res Mol Brain Res 1994; 27: 63-70.
217. Haour FG, Ban EM, Milon G, Baran D, Fillion GM. Brain interleukin-1 receptors. Characterization and modulatino after lipoolysaccharide injection. Prog Neuroendocrinoimmunol 1990; 3: 196-204.
218. Takao T, Tracey DE, Mitchell WM, De Souza EB. Interleukin-1 receptors in mouse brain: Characterization and neuronal localization. Endocrinology 1991; 127: 3070-8.
219. Konsman JP, Kelley K, Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience 1999; 89: 535-48.
220. Fleshner M, Goehler LE, Hermann J. Relton JK, Maier SF, Watkins LR. Interleukin-1B induced corticosterone elevation and hypothalamic NE depletion is vagally meidated. Brain Res Bull 1995; 37: 605-10.
221. Watkins LR, Wiertelak EP, Goehler LE, Mooney-Heiberger K, Martinex J, Furness L, et al. Neurocircuitry of illness-induced hyperalgesia. Brain Res 1994; 639: 283-99.
222. Konsman JP, Luheshi GN, Bluthe RM, Dantzer R. The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis. Eur J Neurosci 2000; 12: 4434-46.
223. Cleeland SC, Bennett GJ, Dantzer R, Dougherty PM, Dunn AJ, Meyers CA, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer 2003; 97: 2919-25.
224. Wolfe F, Michaud K. Fatigue, rheumatoid arthritis, and anti-tumornecrosis factor therapy: An investigation in 24,831 patients. J Rheumatol 2004; 31: 2115-20.
225. Feldmanin M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 63-96.
226. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 1999; 38: 3-7.
227. van Roon JA, Bijlsma JW, Lafeber FP. Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr Opin Investig Drugs 2002; 3: 1011-6.
228. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: The role of interleukin-1 receptor antagonist. Semin Arthritis Rheum 2001; 30:1-6.
229. Fox, D. The role of T cells in the immunopathogenesis of rheumatoid arthritis: New perspectives. Arthritis Rheum 1997; 40: 598-609.
230. Burmester G. Stuhlmuller B, Keyszer G, Kinne R. Mononuclear phagocytes and rheumatoid synovitis: Mastermind or work horse in arthritis? Arthritis Rheum 1997; 40: 5-18.
231. Albino-Teixeira A, Azevedo I, Branco D, Rodrigues-Pereira E, Osswald W. Sympathetic denervation caused by long-term noradrenaline infusions; prevention by desiprimine and superoxide dismutase. Br J Pharmacol 1989; 97: 95-102.
232. Lindenau S, Scholze S, Odendahl M, Dormer T, Radbruch A, Burmester GR, et al. Aberrant activation of B cells in patients with rheumatoid arthritis. Am NY Acad Sci 2003; 987: 246-8.
233. Neeck G, Federlin K, Graef V, Rusch D, Schmidt K. Adrenal secretion of cortisol in patients with rheumatoid arthritis. J Rheumatol 1990; 17: 24-9.
234. Gudbjornsson B, Skogseld B, Oberg K, Wide L, Hallgren R. Intact adrenocorticotropic hormone secretion but impaired cortisol response in patients with active rheumaotid arthritis: Effects of glucocorticoids. J Rheumatol 1996; 23: 596-602.
235. Straub R, Cutolo M. Involvement of the hypothalamic-pituitary-adrenal/ gonadal axis and the peripheral nervous sytem in rheumatoid arthritis: viewpoint based on a systemic pathogenetic role. Arth Rheum 2001; 44:493-507.
236. Morand EF, Cooley H, Leech M, Littlejohn GO. Advances in the understanding of neuroendocrine function in rheumatic disease. Aust N Z J Med 1996; 26: 543-51.
237. Elenkov IJ, Chrousos GP. Stress, cytokine patterns and susceptibility to disease. Baillieres Best Pract Res Clin Endocrinol Metab 1999; 13:583-95.
238. Arend W, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosos factor alpha in rheumatoid arthritis. ArthRheum 1995; 38: 151-60.
239. Buckingham JC, Loxley HD, Taylor AD, Flower RJ. Cytokines, glucocorticoids and neuroendocrine function. Pharmacol Res 1994; 30:35-42.
240. Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrin Metabol 1993; 77: 1690-4.
241. Petrovsky N. Towards a unified model of neuroendocrine-immune interaction. Immunol Cell Biol 2001; 79: 350-7.
242. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES. The sympathetic nerve-an integrative interface between two supersystems: The brain and the immune system. Pharmacol Rev 2000; 52: 595-638.
243. Rogausch H, delRey a, Kabiersch A, Reschke W, Ortel J, Besedovsky H. Endotoxin impedes vasoconstriction in the spleen: Role of endogenous interleukin-1 and sympathetic innervation. Am J Physiol 1997; 272: R2048-54.
244. Kannan H, Tanaka Y, Kunitake T, Ueta Y, Hayashida Y, Yamashita H. Activation of sympathetic outflow by recombinant human interleukin-1 beta in conscious rats. Am J Physiol 1996; 270: R479-85.
245. Terao A, Kitamura H, Asano A, Kobayashi M, Saito M. Roles of prostaglandins D2 and E2 in interleukin-1-induced activation of norepinephrine turnover in the brain and peripheral organs of rats. J Neurochem 1995; 65:2742-7.
246. Webster E, Torpy D, Elenkov I, Chrousos G. Corticotrophin-Releasing Hormone and Inflammation. Ann NY Acad Sci 1998; 840:21-32.
247. Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Engl J Med 1995; 332:1351-62.
248. Sanders VM, Kohm AP. Sympathetic nervous system interaction with the immune system. Brain Behav Immunity 2002; 52: 55-67.
249. Madden KS. Catecholamines, sympathetic innervation, and immunity. Brain Behav Immun 2003; 17 Suppl: S5-10.
250. Cutolo M. The role of the hypothalamus-pituitary-adrenocortical and -gonadal axis in rheumatoid arthritis. Clin Exp Rheumatol 1998; 16:3-6.
251. Walker J, Littlejohn G, McMurray N, Cutolo M. Stress system response and rheumatoid arthritis: A multilevel approach. Rheumatology 1999; 38: 1050-7.
252. O'Leary A. Stress, emotion, and human immune function. Psychol Bull 1990; 108: 363-82.
253. McEwen B, Biron C, Brunson E, Bulloch K, Chambers W, Dhabhar F, et al. The role of adrenocorticoids as modulators of immune functions in health and disease: Neural, endocrine and immune interactions. Brian Res Rev 1997; 23: 79-133.
254. Bellinger D, Lorton D, Lubahn C, Felten D. Innervation of lymphoid organs-Association of nerves with cells of the immune system and their implications in disease In: Ader R, Felten DL, Cohen N Eds. Psychoneuroimmunology, San Diego, Academic Press 2001; 55-111.
255. Chrousos G, Gold P. The concepts of stress and stress system disorders: Overview of physical and behavioral homeostasis. J Am Med Assoc 1992; 267: 1244-52.
256. Chikanza I, Petrou P, Kingsley G, Chrousos G, Panayi G. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 1281-8.
257. Hill S, Ullac A, Starness W, Holley A. Corticosteroids in rheumatoid arthritis. Arch Intern Med 1993; 112:603-11.
258. Cash J, Crofford L, Gallucci W, Sternberg E, Gold P, Chrousos G, et al. Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. J Rheumatol 1992; 19: 1692-6.
259. Masi A, Chrousos G. Hypothalamic-pituitary-adrenal-glucocorticoid axis function in rheumatoid arthritis. J Rheumatol 1996; 23: 577-81.
260. Hermann M, Scholmerich J, Straub R. Stress and rheumatic disease. Rheum Dis Clin North Am 2009; 26: 737-63.
261. Zautra A, Hoffman J, Potter P, Matt KS. Examination of changes in interpersonal stress as a factor in disease exacerbations among women with rheumatoid arthritis. Ann Behav Med 1997; 19: 279-86.
262. Zaufra A, Burleson MH, Matt KS, Roth S, Burrows L. Interpersonal stress, depression, and disease activity in rheumatoid arthritis and osteoarthritis patients. Health Psychol 1994; 13: 2-10.
263. Zautra AJ, Hoffman J, Matt KS, Yocum D, Potter PT, Castro WL, et al. An examination of individual differences in the relationship between stress and disease activity in rheumatoid arthritis. Arthritis Care Res 1998; 11: 271-9.
264. Levine J, Dardick S. Basbaum A, Scipio E. Reflex neurogenic inflammation. I. Contribution of the periheral nervous system to spatially remote inflammatory responses that follow injury. J Neurosci 1985; 5: 1380-6.
265. Levine J, Dardick S, Roizen M, Helms C, Basbaum A. Contribution of sensory afferents and sympathetic efferents to joint injury in experimental arthritis. J Neurosci 1986; 6: 3423-9.
266. Levine J, Goetzl E, Basbaum A. Contribution of the nervous system to the pathophysiology of rheumatoid arthritis and other polyarthritides, Rheumatic Dis Clin North Am Anonymous 1991; 369-83.
267. Lorton D, Lubahn C, Klein N, Schaller J, Bellinger D. Dual role for noradrenergic innervation of lymphoid tissues and arthritic joints in adjuvant-induced arthritis. Brian Behav Immun 1999; 13: 315-34.
268. Colpaert F, Donnerer J, Lembeck F. Effects of capsaicin on inflammation. Life Sci 1983; 32: 1827-34.
269. Lorton D, Lubahn C, Schaller J, Lindquist C, Washington C, Bellinger D. Evidence of an injury/sprouting response of noradrenergic nerves supplying the spleen of Lewis rats with adjuvant-induced arthritis. J Comp Neurol 2005.
270. Lorton D. Lubahn C, Bellinger D. Introduction to biological signaling in psychoneuro-immunology. In: Ader R, Felten DL, Cohen, N Eds. Psychoneuroimmunology. San Diego, Academic Press 2001; 113-60.
271. Rouppe van der Voort C, Kavelaars A, van den Poll T, Heijnen C. Neuroendocrine mediators up-regulate alpha1b- and alpha1d-adrenergic receptor subtypes in human monocytes. J Neuroimmunol 1999; 1: 165-73.
272. Baerwald C, Graefe C, von Wichert P, Krause A. Decreased density of beta-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatoid arthritis. J Rheumatol 1992; 19: 204-10.
273. Lubahn CL, Schaller JA, Bellinger DL, Sweeney S, Lorton D. The importance of timing of adrenergic drug delivery in relation to the induction and onset of adjuvant-induced arthritis. Brain Behav Immun 2004; 18: 563-71.
274. Baraf HS. Efficacy of the newest COX-2 selective inhibitors in rheumatic disease. Curr Pharm Des 2007; 13(22): 2228-36.
275. Kulkarni RG, Achaiah G, Sastry GN. Novel targets for antiinflammatory and antiarthritic agents. Curr Pharm Des 2006; 12(19): 2437-54.
276. Murakami M, Kudo I. Prostaglandin E synthase: A novel drug target for inflammation and cancer. Curr Pharm Des 2006; 12(8): 943-54.